What to Expect at the Retatrutide Seventh Circuit Hearing on 24 September

What's New: The Hearing Is Now Five Days Out

We first reported in August that the US Court of Appeals for the Seventh Circuit had set 24 September 2026 for oral arguments in Eli Lilly's appeal over how retatrutide should be classified — as a small-molecule-style drug reviewable under a New Drug Application (NDA), or as a biological product reviewable under a Biologics License Application (BLA).[4] With the date now close, legal and trade commentary has shifted from noting the hearing exists to previewing what each side will actually argue when it happens — which is what this update covers.

For the full background — the amino-acid-counting dispute, the September 2025 district court ruling, and Lilly's February 2026 notice of appeal — see our original classification-fight report and our hearing-date confirmation from 22 August.

What Is Each Side Expected to Argue?

The underlying procedural posture is narrower than it sounds. Commentary tracking the case has noted that the district court's September 2025 ruling, decided on cross-motions for summary judgment, resolved every claim the parties had put before it: it agreed retatrutide falls short of the strict >40-amino-acid definition of a “protein,” but held the FDA's separate test for what counts as “analogous to a protein” was applied arbitrarily, and remanded that narrower question back to the agency.[1] That means the case is not being re-litigated from scratch on appeal — the question for the Seventh Circuit is whether the district court's remedy (send it back to the FDA) was sufficient, or whether the appellate court should go further.

A 10 September 2026 analysis in Reason magazine frames the underlying stakes bluntly: the dispute is nominally about a molecular technicality, but its practical effect is on how long Lilly can keep “molecular copycats” off the market once retatrutide is approved, and by extension on how soon prices could fall.[2] That is the same exclusivity math we set out in our original classification-fight guide: roughly 12 years of biosimilar exclusivity under a BLA versus about five years of new-chemical-entity exclusivity under an NDA.[3]

Why Is the Timing Awkward for Everyone Involved?

The hearing lands six days before Eli Lilly is scheduled to present full TRIUMPH-2 Phase 3 data for retatrutide at a dedicated symposium at the EASD annual meeting in Milan on 30 September 2026 — a presentation we covered separately.[5] The two events are legally unconnected: nothing argued in Chicago on 24 September changes what the Milan data show, and nothing presented in Milan is evidence in the appeal. But the juxtaposition captures the position Lilly is in — a clinical data package the company has called complete, sitting behind a Q1 2027 filing target that still does not know, five days before its own court date, whether it will be a BLA or an NDA.

What Happens After 24 September?

Federal appellate panels do not rule from the bench. After hearing argument, a three-judge panel typically deliberates for weeks to several months before issuing a written opinion, and a technical regulatory-classification question of this kind tends to sit toward the slower end of that range. A decision before very late 2026 is plausible but not guaranteed, and it is entirely possible the ruling lands close to, or even after, Lilly's own Q1 2027 filing target.

The two tracks — the appeal and the FDA's own remand analysis — also remain independent of each other. In principle, the FDA could issue a new determination on remand before the Seventh Circuit rules, or the reverse; whichever comes first could still be challenged further by the losing side. Lilly has previously stated it can proceed with a marketing application under either application type if the classification question is still open when it files, so the litigation is not expected by itself to delay the underlying regulatory submission.

Does This Affect UK Research-Reagent Supply?

No. This remains a US federal dispute over which American regulatory pathway a licensed pharmaceutical company must use to seek marketing approval for an investigational drug. It has no bearing on the UK regulatory position for research reagents, which sits under the Human Medicines Regulations 2012 and MHRA guidance — see our guide on whether research peptides are legal in the UK. Retatrutide remains unlicensed for human use everywhere, regardless of how the classification question or the 24 September hearing resolve.

Retatrutide is supplied as a research reagent only. It is not a medicine and has not been evaluated by the MHRA or FDA. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.

Frequently Asked Questions